New Frontiers in 3D Cell Technologies

Fostering discussion of transformative 3D in vitro cell technologies  from advanced disease modeling to organ-on-a-chip solutions

Virtual KOL Roundtables ●  In-person and Digital Symposia ●  Curated 3D In Vitro News Digests

Are you ready for the future of preclinical drug testing?

Organ on a chip systems | scalable 3D disease modeling platforms | animal testing alternatives | highly predictive drug safety screening

Join the conversion.  Help shape the future.

New Frontiers in 3D Technologies is going digital!  This year we’re introducing a virtual roundtable series featuring key opinion leaders who are on a mission to transform drug discovery and safety testing. We’re also planning a virtual symposium that will bring together pharma and biotech thought-leaders, research scientists, and regulatory experts to discuss innovative new 3D cell technologies for drug efficacy and safety testing.  To help you stay informed about movers and shakers in 3D, we’ve launched a curated news digest focused on 3D in vitro breakthroughs.  Our aim is to make it easy and convenient for us all to stay in touch and stay informed during this pandemic and beyond. 

  • Learn about practical applications for the latest generation of 3D in vitro models that have successfully transitioned from R&D evaluations to indispensable for everyday use in industry
  • Discuss 3D technology trends and real-world implementation challenges
  • Discover disease modeling platforms, assay strategies, and readout techniques that could transform how your organization does drug discovery and development
  • Debate how best to apply emerging tools for organ-on-a-chip systems.
  • Network with influencers in the fields of metabolic disease, oncology, and toxicology
  • Share how you are applying 3D cell-based technology in your work by submitting an abstract for a poster or oral presentation. 

organs-on-Chip Networks

Human Disease Modeling

Alternatives to Animal testing

Drug Safety Screening

Featured Roundtable Event

January 26, 2021
7 AM PST | 10 AM EST | 4 PM CET

Animal-Free Drug Safety Testing:  Challenges and Opportunities

Join us for a engaging discussion on the future of animal-free drug safety testing, featuring three visionaries in the field who are working to push biomedical research and the pharmaceutical industry forward toward safer, more predictive, dare we say more human in silico and in vitro models.

Prof. Thomas Hartung

Prof. Thomas Hartung is a Professor of Evidence-based Toxicology and Director of the Center for Alternatives to Animal Testing at Johns Hopkins University Bloomberg School of Public Health, and Professor of Pharmacology and Toxicology at the University of Konstanz. He is a passionate advocate for replacing animal testing with more ethical and predictive in vitro models.

Prof. Armin Wolf

Prof. Armin Wolf is the Chief Scientific Officer at InSphero and a Professor of Toxicology at the Technical University of Kaiserslautern, Germany.  An accomplished pharma R&D executive and board-certified toxicologist with more than 30 years of cumulative experience at Novartis and Janssen, Armin is a leading expert in mechanistic and investigative safety and discovery.

Dr. Stefan Platz

Dr. Stefan Platz is Senior Vice President and Head of Clinical Pharmacology and Safety Services, R&D, at AstraZeneca. He is a passionate scientist globally leading clinical pharmacology, pharmacometrics, bioanalytics as well as toxicology and pathology.

Call for Abstracts

New Frontiers in 3D invites scientists, bioengineers, academic researchers, and innovation leaders to submit abstracts featuring innovative applications of 3D Cell Technology for consideration for poster and oral presentations at our 2021 meeting.  Check back for details and abstract submission guidelines.

Sponsorship Opportunities

New Frontiers in 3D plans to invite a select group of innovative 3D cell-based solution providers to sponsor our 2021 virtual meeting and showcase products that we believe will be of interest to scientists, researchers, regulatory agencies, and others in the field. If you haven’t already received an invitation to participate, contact us for more information.